Salsalate, a prodrug of salicylate, is associated with lower glycated hemoglobin levels and markers of inflammation in patients with type 2 diabetes, according to a multicenter study in the Annals of Internal Medicine.
Researchers randomized some 290 patients with poorly controlled diabetes to add-on therapy with either salsalate or placebo for 48 weeks. By study’s end, the mean glycated hemoglobin level was 0.37% lower in the salsalate group than in the placebo group. Fasting glucose levels dropped an average 15 mg/dL more with salsalate. Leukocyte and neutrophil counts were also lower with salsalate.
There were, however, modest increases in LDL cholesterol, weight, and urinary albumin that the authors say “warrant further assessment” before salsalate can be recommended for general use in diabetes.
Source: Annals of Internal Medicine